Biomarkers as Surrogate Endpoints in Cancer Trials

Seminars in Oncology Nursing

Volumn 28, Issue 2, 2012, Pages 99-108

  Dunn, Barbara K ^a   Akpa, Esther ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer trials; Clinical endpoints; Surrogate endpoint biomarkers

Indexed keywords

TUMOR MARKER;

ARTICLE; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; METHODOLOGY; NEOPLASM; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860245271     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.03.006     Document Type: Article

References (34)

1. Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002, 18:41-46.
2. Schatzkin A., Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002, 2:19-27.
3. Fleming T.R. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005, 24:67-78.
4. Fleming T.R., DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 1996, 125:605-613.
5. Berruti A., Generali D., Bertaglia V., et al. Intermediate endpoints of primary systemic therapy in breast cancer patients. J Natl Cancer Inst Monogr 2011, 2011:142-146.
6. Kelloff G.J., Lippman S.M., Dannenberg A.J., et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006, 12:3661-3697.
7. Fabian C.J., Kimler B.F., Mayo M.S., et al. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005, 12:185-213.
8. Schatzkin A., Freedman L.S., Schiffman M.H., et al. Validation of intermediate end points in cancer research. J Natl Cancer Inst 1990, 82:1746-1752.
9. Prentice R.L. Surrogate endpoints in clinical-trials - definition and operational criteria. Stat Med 1989, 8:431-440.
10. Tice J.A., Cummings S.R., Smith-Bindman R., et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008, 148:337-347.
11. McTiernan A., Chlebowski R.T., Martin C., et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 2009, 27:6135-6143.
12. Chow C.K., Venzon D., Jones E.C., et al. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000, 9:917-921.
13. Freedman M., San Martin J., O'Gorman J., et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001, 93:51-56.
14. Cuzick J., Warwick J., Pinney E., et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011, 103:744-752.
15. Fabian C.J., Kimler B.F. Use of biomarkers for breast cancer risk assessment and prevention. J Steroid Biochem Mol Biol 2007, 106:31-39.
16. Fabian C.J., Kimler B.F., Anderson J., et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 2004, 10:5403-5417.
17. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005, 23:1636-1643.
18. Goss P.E., Ingle J.N., Ales-Martinez J.E., et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391.
19. Frank D.H., Kimler B.F., Fabian C.J., et al. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months. Breast Cancer Res Treat 2009, 115:661-668.
20. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.
21. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008, 8:1377-1385.
22. Arun B., Valero V., Logan C., et al. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 2007, 13:4943-4948.
23. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
24. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
25. Ruckle H.C., Klee G.G., Oesterling J.E. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc 1994, 69:69-79.
26. Kubicek G.J., Naguib M., Redfield S., et al. PSA decrease during combined-modality radiotherapy predicts for treatment outcome. Int J Radiat Oncol Biol Phys 2010, 78:759-762.
27. Demark-Wahnefried W., Polascik T.J., George S.L., et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008, 17:3577-3587.
28. Itzkowitz S.H. Incremental advances in excremental cancer detection tests. J Natl Cancer Inst 2009, 101:1225-1227.
29. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-895.
30. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-884.
31. Meyskens F.L., McLaren C.E., Pelot D., et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008, 1:32-38.
32. Aberle D.R., Adams A.M., Berg C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
33. Vourlekis J.S., Szabo E. Use of markers for the detection and treatment of lung cancer. Dis Markers 2004, 20:71-85.
34. Lam S., McWilliams A., LeRiche J., et al. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006, 15:1526-1531.